Suppr超能文献

一种新鉴定的 SARS-CoV-2 刺突蛋白非 RBD 区域线性表位提高了 COVID-19 患者的血清学检出率。

A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients.

机构信息

West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, PR China.

Food Safety Monitoring and Risk Assessment Key Laboratory of Sichuan Province, Department of Public Health Laboratory Sciences, West China School of Public Health, Sichuan University, Chengdu, PR China.

出版信息

BMC Microbiol. 2021 Jun 26;21(1):194. doi: 10.1186/s12866-021-02241-y.

Abstract

BACKGROUND

Serological test is helpful in confirming and tracking infectious diseases in large population with the advantage of fast and convenience. Using the specific epitope peptides identified from the whole antigen as the detection antigen is sensitive and relatively economical. The development of epitope peptide-based detection kits for COVID-19 patients requires comprehensive information about epitope peptides. But the data on B cell epitope of SARS-CoV-2 spike protein is still limited. More importantly, there is a lack of serological data on the peptides in the population. In this study, we aimed to identify the B cell epitope peptides of spike protein and detect the reactivity in serum samples, for further providing data support for their subsequent serological applications.

RESULTS

Two B cell linear epitopes, P104 and P82, located in non-RBD region of SARS-CoV-2 S protein were identified by indirect ELISA screening of an overlapping peptide library of the S protein with COVID-19 patients' convalescent serum. And the peptides were verified by testing with 165 serum samples. P104 has not been reported previously; P82 is contained in peptide S21P2 reported before. The positive reaction rates of epitope peptides S14P5 and S21P2, the two non-RBD region epitopes identified by Poh et al., and P82 and P104 were 77.0%, 73.9%, 61.2% and 30.3%, respectively, for 165 convalescent sera, including 30 asymptomatic patients. Although P104 had the lowest positive rate for total patients (30.3%), it exhibited slight advantage for detection of asymptomatic infections (36.7%). Combination of epitopes significantly improved the positive reaction rate. Among all combination patterns, (S14P5 + S21P2 + P104) pattern exhibited the highest positive reaction rate for all patients (92.7%), as well as for asymptomatic infections (86.7%), confirming the feasibility of P104 as supplementary antigen for serological detection. In addition, we analyzed the correlation between epitopes with neutralizing antibody, but only S14P5 had a medium positive correlation with neutralizing antibody titre (r = 0.510, P < 0.01).

CONCLUSION

Our research proved that epitopes on non-RBD region are of value in serological detection especially when combination more than one epitope, thus providing serological reaction information about the four epitopes, which has valuable references for their usage.

摘要

背景

血清学检测在大规模人群中具有快速、便捷的优势,有助于确认和跟踪传染病。使用从整个抗原中鉴定出的特定表位肽作为检测抗原具有敏感性和相对经济性。开发针对 COVID-19 患者的基于表位肽的检测试剂盒需要全面了解表位肽的信息。但是,关于 SARS-CoV-2 刺突蛋白 B 细胞表位的数据仍然有限。更重要的是,人群中缺乏针对这些肽的血清学数据。在这项研究中,我们旨在鉴定刺突蛋白的 B 细胞线性表位肽,并检测血清样本中的反应性,为进一步为其随后的血清学应用提供数据支持。

结果

通过间接 ELISA 筛选 COVID-19 患者恢复期血清与 SARS-CoV-2 S 蛋白重叠肽文库,鉴定出两个位于 S 蛋白非 RBD 区域的 B 细胞线性表位 P104 和 P82。并通过对 165 个血清样本进行测试验证了这些肽。P104 以前没有报道过;P82 包含 Poh 等人之前报道的肽 S21P2。针对 165 个恢复期血清(包括 30 个无症状患者),鉴定出的两个非 RBD 区域表位 S14P5 和 S21P2,以及 P82 和 P104 的阳性反应率分别为 77.0%、73.9%、61.2%和 30.3%。尽管 P104 在总患者中的阳性率最低(30.3%),但它对无症状感染的检测有轻微优势(36.7%)。表位的组合显著提高了阳性反应率。在所有组合模式中,(S14P5+S21P2+P104)模式对所有患者(92.7%)和无症状感染(86.7%)的阳性反应率最高,证实了 P104 作为血清学检测补充抗原的可行性。此外,我们分析了表位与中和抗体之间的相关性,但只有 S14P5 与中和抗体滴度呈中度正相关(r=0.510,P<0.01)。

结论

我们的研究证明,非 RBD 区域的表位在血清学检测中具有价值,特别是当组合使用多个表位时,从而为这四个表位提供了血清学反应信息,这对它们的使用具有有价值的参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/205c/8236163/80fefc8a35e1/12866_2021_2241_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验